Company profile
Accium BioSciences company profile
Developer of an ultrasensitive detection platform designed to overcome challenges faced in clinical development of novel drugs. The company's ultrasensitive detection platform investigates pharmacologic and pharmacodynamic endpoints of Merck's Temodar® in glioblastoma multiforme (GBM) patients, providing 14C-methylation measurements of tumor DNA after 14C-Temodar® administration. The purpose of the study is to identify pharmacologic or pharmacodynamic endpoints that may be predictive of response to therapy in individual patients, enabling clinicians to involve therapeutic response prediction and resistance to treatment.
Business identity
- Website
- https://www.acciumbio.org
- Contact email
- [email protected]
- Phone number
- 206.258.8860
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00001-00010 employees
- Revenue range
- $1K+
- Founded
- 2004-05-01
Headquarters
- Headquarters
- Seattle, United States, Washington
- Postal code
- 98122
- Country code
- US
- Continent
- North America